BGPT: Author Review: Satabdee Mohapatra

Fuel Your Discoveries

Quick Explanation Copied

Satabdee Mohapatra — scientific profile (evidence-limited review)

Based on the specific, DOI-verifiable works provided (notably Tau/prion phase separation biophysics and aggregation modulation), the author’s portfolio shows a consistent focus on protein condensation / phase behavior and biophysical mechanisms across neurodegenerative and peptide-aggregation systems, with at least one high-impact primary research study in Science Advances (), complemented by aggregation/condensation work on Tau and a cytoskeleton-linked condensation review ().

Long Explanation

Author Review: Satabdee Mohapatra

Evidence basis (strict): only the DOI-verifiable papers explicitly included in your prompt.

Because your message provides titles and (for some) DOIs/citation counts, I restrict scientific claims to what is directly supported by the cited works below. I do not infer missing experimental details, methods, or results beyond what the cited sources describe in their records/metadata.

1) Visual map of the author’s apparent scientific niche (from DOI-verifiable works)

Counts reflect only the DOI-verifiable items you provided (no attempt to include all 14 papers).

2) Evidence-based critique: what the cited works indicate (and what remains uncertain)

A. Phase separation / condensation as a mechanistic through-line

The author’s set includes works that frame neurodegeneration-relevant aggregation in terms of phase separation/condensation and its modulation by specific biochemical factors.

Prion protein (PrP) + copper: Copper is reported to drive PrP phase separation and modulate aggregation, tying copper dyshomeostasis to prion pathology via a biophysical route (phase behavior) rather than only correlation.
Tau aggregation/condensation regulation: The author is included on a study where stoichiometric binding (14-3-3ζ) is reported to promote phospho-Tau microtubule dissociation while also reducing aggregation and condensation—suggesting binding stoichiometry can alter the balance between functional states and pathological condensate formation.
Condensation at the interface with cytoskeletal architecture (review): A review explicitly connects biomolecular condensation to cytoskeletal regulation of cellular organization and dynamics. As a review, it is informative for framing hypotheses, but it is not itself an experimental proof of a specific mechanism.

What is strong: The portfolio is plausibly mechanistic (phase/condensation language appears repeatedly) rather than purely descriptive.
What I cannot verify from your prompt alone: experimental specifics (e.g., concentrations, imaging modalities, whether in vitro findings replicate in cellular/animal contexts) and quantitative endpoints (e.g., exact kinetic shifts, dose-response curves). Those details would be essential to judge whether conclusions generalize.

B. Biophysical aggregation modulation via small molecules / conjugates

Several works involve chemical modulation of amyloidogenic peptides/proteins.

α-Synuclein aggregation inhibition (mannitol-based small molecules): The author co-authors a study positioned around inhibiting α-synuclein aggregation relevant to Parkinson’s disease.
Glycosylation-like conjugates targeting tau-derived aggregation: Tryptophan–glucosamine conjugates are described as modulating aggregation of tau-derived PHF6-peptide, using combined in vitro and in silico approaches.
PAP(248–286) semen amyloid / infection enhancement context: A study reports inhibitory effects of a naphthoquinone–tryptophan hybrid toward aggregation of PAP f39 semen amyloid, with PAP aggregation framed as facilitating retroviral attachment/infection enhancement.

Critical lens: For aggregation-modulator studies, a key scientific weakness risk is that aggregation inhibition in vitro may not translate to cellular toxicity pathways or in vivo pharmacodynamics. Your prompt does not provide whether these studies include orthogonal assays (e.g., cytotoxicity, seed-dependent aggregation inhibition, or structural/biophysical confirmation) at the needed rigor. I therefore treat these as mechanistically suggestive rather than conclusive on therapeutic relevance.

C. In silico enzyme targeting (black tea components)

The author also appears on work performing in silico investigation of black tea components on digestive enzymes relevant to diabetes/obesity contexts.

In silico docking/interaction study claims: A study is explicitly titled as in silico investigation of black tea components on α-amylase, α-glucosidase, and lipase.

Skeptical note: Purely in silico studies have high false-positive risk unless followed by experimental validation (enzyme inhibition assays, concentration realism, ADMET constraints, etc.). Without such validation details in your provided text, I score this sub-area as lower evidential strength toward causal biological claims.

D. What to look for to judge rigor (actionable reviewer checklist)

If you want to audit the author’s scientific strength beyond titles/DOIs, the most discriminating items (especially for phase separation/aggregation chemistry) are:

Reproducibility: independent biological/technical replicates and sensitivity analyses.
Quantification: kinetic/thermodynamic metrics, not just endpoint microscopy/ThT signals.
Orthogonality: multiple independent readouts (e.g., FRAP + SAXS/FTIR + toxicity assays, when relevant).
Controls: non-binding analogs, seed controls, and stoichiometry controls for condensate biology.
Translatability: cellular/organotypic relevance when claiming disease mechanism.

I can’t verify these points from your prompt alone; however, the citations above provide the starting targets for direct inspection.

3) Mini “evidence table” of DOI-verifiable works (what the cited record says)

This table lists only items that include DOIs in your prompt. Cells are factual summaries limited to the cited record excerpt/metadata.

Topic	Citation (DOI)	Evidence strength (for causal claims)	Key scientific claim (as described)
Prion protein / copper / phase separation	10.1126/sciadv.adi7347	Strong (primary mechanism + high-impact venue implied)	Copper is reported to drive PrP phase separation and modulate aggregation
Tau / 14-3-3ζ / phospho-Tau / condensation & aggregation	10.1038/s42003-025-08548-0	Moderate (mechanistic biophysics described; full rigor needs inspection)	Stoichiometric 14-3-3ζ binding promotes phospho-Tau microtubule dissociation and reduces aggregation/condensation
Tau-derived aggregation (PHF6) / conjugates	10.1039/c9cc06868f	Moderate (biophysical modulation with in silico + in vitro framing)	Tryptophan–glucosamine conjugates modulate PHF6 aggregation at low concentrations
α-Synuclein / aggregation inhibition (mannitol-based small molecules)	10.3389/fmolb.2019.00016	Moderate (aggregation inhibition is plausible; translation uncertain)	Mannitol-based small molecules inhibit α-synuclein amyloid aggregation
PAP f39 semen amyloid / naphthoquinone–tryptophan hybrid	10.3390/molecules23123279	Moderate (amyloid aggregation effects; biological inference depends on downstream validation)	Hybrid is reported to inhibit PAP f39 aggregation
Cytoskeleton condensation (review synthesis)	10.1016/j.brainresbull.2023.01.009	Moderate (conceptual synthesis; not direct experimental proof)	Condensation processes are discussed as intersecting with cytoskeletal regulation
Black tea components / digestive enzymes (in silico)	10.7324/japs.2015.501207	Weak (in silico alone; validation missing in your prompt)	In silico interactions with α-amylase, α-glucosidase, lipase are used to propose mechanism

4) Strength-of-evidence verdict (with falsifiability focus)

Most defensible strengths (from your DOI-verifiable set)

Mechanistic biophysics emphasis: copper–PrP and 14-3-3ζ–phospho-Tau works explicitly target mechanistic levers affecting phase behavior/aggregation .
Cross-system conceptual portability: aggregation/condensation modulation appears across Tau, PrP, α-synuclein, and PAP f39 contexts—consistent with a coherent theme (condensation/aggregation as a unifying lens). .

Key uncertainty / blind spots (cannot be resolved from prompt)

Translation validity: for aggregation modifiers (small molecules/conjugates), in vitro aggregation readouts do not guarantee cellular pathway modulation; you would need the papers’ downstream assays.
Model system scope: phase separation often depends on buffer composition, protein concentration, crowding, and post-translational modifications; the prompt does not include those constraints.
In silico limitation: the black tea enzyme docking study is explicitly in silico; without experiments, causal claims are weak. .

What would most disprove the implied mechanistic storyline?

For condensate/aggregation mechanisms: if binding/phase-separation modifiers fail to reproduce effects under more physiological conditions (cellular condensates, relevant concentrations, PTM states) despite in vitro success.
For aggregation inhibition: if structural assays show no meaningful shift in aggregate populations beyond assay artifacts, or if cell-based toxicity pathways do not track aggregation-state changes.
For in silico claims: if experimental enzyme assays do not support predicted binding or if binding is not achievable at relevant concentrations.

Further BGPT actions (optional)

Feedback:

Updated: April 13, 2026